Louis. She is the lead author of a new study that estimated the amount of time people might continue to perform daily activities without assistance after beginning lecanemab, marketed as Leqembi, or donanemab, marketed as Kisunla. “Patients want to know how long a drug will allow the...
At the same time, researching, developing, and ultimately manufacturing gene therapies to address them is expensive. Often, funding for these treatments is raised through family or charitable foundations, so it’s imperative that we make every dollar count along this jour...
Louis. She is the lead author of a new study that estimated the amount of time people might continue to perform daily activities without assistance after beginning lecanemab, marketed as Leqembi, or donanemab, marketed as Kisunla. “Patients want to know how lo...
Now, with expensive and risky new drugs coming to market that promise to slow the progression of the disease, there’s new urgency for improved diagnosis. Getting the diagnosis right “Getting the diagnosis right is absolutely critical to be able to provide these new th...